Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 2 3Phase 1 3Phase 3 2Phase NA 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Lymphoid 1

Conditions

Solid Tumors 1Small Cell Lung Carcinoma 1Recurrence 1Lymphoma, Non-Hodgkin 1Hereditary Sensory and Autonomic Neuropathies 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × chiauranib × Clear all
NCT03216343 2023-08-30

Phase Ib/II Study of Chiauranib in Patients With Small Cell Lung Cancer

Chipscreen Biosciences, Ltd.

Phase 1 Completed
48 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT03074825 2019-07-24

Study of Chiauranib in Relapsed/Refractory Non-Hodgkin's Lymphoma

Chipscreen Biosciences, Ltd.

Phase 1 Terminated
5 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Hereditary Sensory and Autonomic Neuropathies, Recurrence

NCT02122809 2016-06-17

Phase I Study of Chiauranib in Patients With Advanced Solid Tumors

Chipscreen Biosciences, Ltd.

Phase 1 Completed
18 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡